

## POLAR3<sup>◇</sup> Total Hip Solution delivers high survivorship at 11 years, higher than class average patient satisfaction and improvements in patient-reported outcome measures (PROMs)<sup>1</sup>

### Overview

- Bespoke implant report produced by the UK NJR (National Joint Registry) summarising usage and outcomes associated with POLAR3, the combination of POLARSTEM<sup>◇</sup>, OXINIUM<sup>◇</sup> femoral head, highly cross-linked polyethylene (XLPE) bearing and R3<sup>◇</sup> cup
- The analysis is based on data collected by the NJR and on PROMs data collected by NHS Digital\*
- Reported POLAR3 usage between July 2007 and September 2023 for:
  - 25,619 total hip replacements (THR)
  - 23,087 total patients
  - 497 implanting surgeons at 104 centres

### Considerations

\*The data used for this analysis was obtained from the NJR Supplier Feedback System. The Healthcare Quality Improvement Partnership ('HQIP') and/or the National Joint Registry ('NJR') take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.

### Results



**97.8%**  
survivorship with  
POLAR3




**38%** Lower revision risk with POLAR3 compared to class average for all other THR with cementless stems at 11 years<sup>1</sup>

### ODEP<sup>2</sup>

10A\* POLARSTEM Cementless Stem  
13A\* R3 Cementless Cup

Patients who received POLAR3...

Were **significantly more likely to be satisfied** with their THR and to consider their procedure a success ( $p < 0.001$ ), after 6 months, compared to those who received all other THR with cementless stems



Achieved **significantly better average 6-month PROM scores** compared to patients who received other types of cementless stems ( $p < 0.001$ )

PROMs	POLAR3	All other THR with NJR cementless stems	p value
Oxford Hip Score	23.1 (22.9–23.3)	21.7 (21.6–21.7)	$p < 0.001$
EQ-5D	0.472 (0.466–0.479)	0.443 (0.442–0.444)	
EQ-VAS	14.7 (14.3–15.2)	12.3 (12.3–12.4)	

Adjusted health gain scores (95% confidence interval) at 6 months after THR. Adjusted scores correspond to the NHS Digital version 3 case-mix-adjustment model. Using case-mix adjusted scores allows for a more accurate comparison between groups by taking into account variations in patient characteristics.

### Conclusions

POLAR3 delivers 11-year survivorship of 97.8%. It also delivers significantly higher patient satisfaction, success outcomes and improvements in PROMs compared to the class average for cementless stems in all other THR patients.

\*NJR data recorded between 2007–2023.

### References:

1. National Joint Registry for England, Wales and Northern Ireland: POLARSTEM Cementless (OXINIUM/XLPE/R3 cup) bespoke implant summary report. 20 October 2023. Copy available upon request. 2. Orthopaedic Data Evaluation Panel (ODEP). Available at: <http://www.odep.org.uk>. Accessed December 22, 2023.

Smith & Nephew, Inc. 1450 Brooks Road, Memphis, TN 38116, USA.  
41816-en V1 01/24. Published January 2024. ©2024 Smith+Nephew. All rights reserved. <sup>◇</sup>Trademark of Smith+Nephew.  
Smith & Nephew Orthopaedics AG, Baar, Switzerland is the legal manufacturer for POLARSTEM. All Trademarks acknowledged.

For detailed product information, including indications for use, contraindications, precautions, and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Developed by Evidence Communications,  
Global Clinical & Medical Affairs  
[www.smith-nephew.com](http://www.smith-nephew.com)